Investing

Coherus Oncology : CHRS

CHRS

Stock Data

$1.50

$0.03 (1.64%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Coherus BioSciences Inc is a biopharmaceutical company based in Redwood City, California, specializing in biosimilars and immuno-oncology treatments. It offers products like UDENYCA, a biosimilar to Neulasta for boosting white blood cells, and CIMERLI, equivalent to Lucentis for various eye conditions. Additionally, it provides YUSIMRY, a biosimilar to Humira for inflammatory diseases. Coherus has formed strategic partnerships with several industry leaders, emphasizing its commitment to affordable healthcare solutions since its rebranding in 2012 from BioGenerics, Inc.

All Coherus Oncology Articles

1 Article

Lee Jackson | May 11, 2026 at 7:58 AM EDT

Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More

Pre-Market Stock Futures: Futures are trading lower as we get set to start the new trading week, as reports indicate…